Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer

Next Previous
Trial Profile

A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Tarlatamab in Combination With YL201 With or Without Anti-PD-L1 in Subjects With Extensive Stage Small Cell Lung Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 27 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tarlatamab (Primary) ; YL 201 (Primary) ; Atezolizumab; Durvalumab
  • Indications Small cell lung cancer
  • Focus Adverse reactions
  • Acronyms DeLLphi-310
  • Sponsors Amgen

Most Recent Events

  • 20 Oct 2025 Planned End Date changed from 21 May 2031 to 23 Apr 2031.
  • 20 Oct 2025 Planned primary completion date changed from 21 May 2031 to 23 Apr 2031.
  • 17 Aug 2025 Planned End Date changed from 13 Apr 2031 to 21 May 2031.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top